{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:17:42Z","timestamp":1769555862285,"version":"3.49.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Proactive therapeutic drug monitoring facilitates early dose optimization to prevent primary and secondary failure to antitumor necrosis factor (TNF). We aimed to investigate the impact of dashboard-guided induction dosing strategy on anti-TNF durability and immunogenicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a single-center cohort analysis of patients with Crohn\u2019s disease (CD) and Ulcerative colitis (UC) who initiated treatment with infliximab or adalimumab between January 2020 and March 2023. Induction was prospectively personalized using a pharmacokinetic model-guided dosing strategy, with drug measurements at week 2, 6, and 14, and the first dose adjustment occurred in week 4. Data were recorded retrospectively. We assessed treatment durability, pharmacokinetic outcomes, clinical remission (CR), and endoscopic remission (ER), at both weeks 24 and 56. Multivariate analysis and Kaplan\u2013Meier curves were used to compare outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We enrolled 147 patients (92 CD \/55 UC). Anti-TNF drug survival probability was 85.00% after a year. Seventy-seven percent of patients were prescribed an intensified dose in the first year, which was associated with improved drug durability. Only 1 patient out of 147 developed antibodies to adalimumab, none to infliximab. After 24 and 52 weeks of treatment 92.5% (136\/147) and 72.78% (107\/147) of patients achieved CR, respectively. ER was observed in 59.39% (79\/133) of patients. The use of immunomodulators or carriage of HLA DQA1*05 variant was not associated with adverse treatment or pharmacokinetic outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Optimizing anti-TNF induction with a dashboard-guide dosing strategy proves to be a valuable approach to enhance treatment durability and clinical outcomes in inflammatory bowel disease patients. Immunogenicity appears to be mitigated by the model, which even mitigates the impact of immunomodulators and overcomes HLA DQA1*05 effect.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otaf023","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T21:35:32Z","timestamp":1750973732000},"source":"Crossref","is-referenced-by-count":1,"title":["Dashboard-Guided Anti-TNF Induction: An Effective Strategy to Minimize Immunogenicity While Avoiding Immunomodulators\u2014A Single-Center Cohort Study"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4943-2181","authenticated-orcid":false,"given":"Elena","family":"C\u00e9spedes-Mart\u00ednez","sequence":"first","affiliation":[{"name":"Unitat d\u2019Atenci\u00f3 Crohn Colitis (UACC), Gastroenterology Department, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Robles-Alonso","sequence":"additional","affiliation":[{"name":"Unitat d\u2019Atenci\u00f3 Crohn Colitis (UACC), Gastroenterology Department, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Serra-Ruiz","sequence":"additional","affiliation":[{"name":"Unitat d\u2019Atenci\u00f3 Crohn Colitis (UACC), Gastroenterology Department, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Herrera-De Guise","sequence":"additional","affiliation":[{"name":"Unitat d\u2019Atenci\u00f3 Crohn Colitis (UACC), Gastroenterology Department, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Mayorga-Ayala","sequence":"additional","affiliation":[{"name":"Unitat d\u2019Atenci\u00f3 Crohn Colitis (UACC), Gastroenterology Department, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Larrosa-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Casellas","sequence":"additional","affiliation":[{"name":"Unitat d\u2019Atenci\u00f3 Crohn Colitis (UACC), Gastroenterology Department, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Borruel","sequence":"additional","affiliation":[{"name":"Unitat d\u2019Atenci\u00f3 Crohn Colitis (UACC), Gastroenterology Department, Vall d\u2019Hebron University Hospital, CIBER-EHD , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"12","key":"2025071502114127100_CIT0001","first-page":"656","article-title":"Etiology and management of lack or loss of response to anti\u2013tumor necrosis factor therapy in patients with inflammatory bowel disease","volume":"15","author":"Fine","year":"2019","journal-title":"Gastroenterol Hepatol."},{"issue":"9","key":"2025071502114127100_CIT0002","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"2025071502114127100_CIT0003","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/apt.14318","article-title":"Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn\u2019s disease: a subanalysis of the DIAMOND trial","volume":"46","author":"Nakase","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"2025071502114127100_CIT0004","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/apt.15643","article-title":"Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease","volume":"51","author":"Gibson","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"S3","key":"2025071502114127100_CIT0005","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1002\/jcph.374","article-title":"Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice","volume":"55","author":"Vande Casteele","year":"2015","journal-title":"J Clin Pharmacol."},{"issue":"12","key":"2025071502114127100_CIT0006","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2025071502114127100_CIT0007","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2025071502114127100_CIT0008","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology."},{"issue":"8","key":"2025071502114127100_CIT0009","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised clinical trial: deep remission in biologic and immunomodulator na\u00efve patients with Crohn\u2019s disease \u2013 a SONIC post hoc analysis","volume":"41","author":"Colombel","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"2025071502114127100_CIT0010","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/apt.15054","article-title":"The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn\u2019s disease: a post hoc analysis","volume":"49","author":"Hyams","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"2025071502114127100_CIT0011","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/gutjnl-2019-319758","article-title":"Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial","volume":"69","author":"Roblin","year":"2020","journal-title":"Gut."},{"issue":"9","key":"2025071502114127100_CIT0012","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1007\/s10620-015-3581-4","article-title":"Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn\u2019s disease patients failing infliximab","volume":"60","author":"Steenholdt","year":"2015","journal-title":"Dig Dis Sci."},{"issue":"3","key":"2025071502114127100_CIT0013","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/crocol\/otaa050","article-title":"Proactive drug monitoring is associated with higher persistence to infliximab and adalimumab treatment and lower healthcare utilization compared with reactive and clinical monitoring","volume":"2","author":"Syed","year":"2020","journal-title":"Crohns Colitis 360."},{"issue":"1","key":"2025071502114127100_CIT0014","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/ibd\/izy203","article-title":"Proactively optimized infliximab monotherapy is as effective as combination therapy in IBD","volume":"25","author":"Lega","year":"2019","journal-title":"Inflamm Bowel Dis."},{"issue":"7","key":"2025071502114127100_CIT0015","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology."},{"issue":"5","key":"2025071502114127100_CIT0016","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1053\/j.gastro.2018.01.004","article-title":"Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn\u2019s disease","volume":"154","author":"D\u2019Haens","year":"2018","journal-title":"Gastroenterology."},{"issue":"4","key":"2025071502114127100_CIT0017","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1053\/j.gastro.2019.06.003","article-title":"Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn\u2019s disease compared with reactive monitoring","volume":"157","author":"Assa","year":"2019","journal-title":"Gastroenterology."},{"issue":"12","key":"2025071502114127100_CIT0018","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1016\/j.cgh.2023.03.044","article-title":"HLA-DQA1*05 Genotype and immunogenicity to tumor necrosis factor-\u03b1 antagonists: a systematic review and meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol [Internet]"},{"issue":"10","key":"2025071502114127100_CIT0019","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/ibd\/izac259","article-title":"Influence of HLADQA1*05 genotype in adults with inflammatory bowel disease and anti-TNF treatment with proactive therapeutic drug monitoring: a retrospective cohort study","volume":"29","author":"Fuentes-Valenzuelaas","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2025071502114127100_CIT0020","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/00365521.2020.1856405","article-title":"Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial","volume":"56","author":"Strik","year":"2021","journal-title":"Scand J Gastroenterol."},{"issue":"9","key":"2025071502114127100_CIT0021","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/ibd\/izab285","article-title":"Dashboard-driven accelerated infliximab induction dosing increases infliximab durability and reduces immunogenicity","volume":"28","author":"Dubinsky","year":"2022","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"2025071502114127100_CIT0022","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/bcp.14229","article-title":"A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease","volume":"86","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2020","journal-title":"Br J Clin Pharmacol."},{"issue":"2","key":"2025071502114127100_CIT0023","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/bcp.14410","article-title":"Bayes-based dosing of infliximab in inflammatory bowel diseases: Short-term efficacy","volume":"87","author":"Santacana Juncosa","year":"2021","journal-title":"Br J Clin Pharmacol."},{"issue":"6","key":"2025071502114127100_CIT0024","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1053\/j.gastro.2022.01.009","article-title":"Failure to achieve target drug concentrations during induction and not HLA-DQA1*05 carriage is associated with antidrug antibody formation in patients with inflammatory bowel disease","volume":"162","author":"Spencer","year":"2022","journal-title":"Gastroenterology."},{"issue":"6","key":"2025071502114127100_CIT0025","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.cgh.2019.09.041","article-title":"How, when, and for whom should we perform therapeutic drug monitoring","volume":"18","author":"Vermeire","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"2025071502114127100_CIT0026","doi-asserted-by":"crossref","first-page":"e057656","DOI":"10.1136\/bmjopen-2021-057656","article-title":"Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn \u2019 s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)","volume":"12","author":"Papamichael","year":"2022","journal-title":"BMJ Open"},{"issue":"April","key":"2025071502114127100_CIT0027","doi-asserted-by":"publisher","first-page":"105369","DOI":"10.1016\/j.ejps.2020.105369","article-title":"Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease","volume":"150","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2020","journal-title":"Eur J Pharm Sci."},{"issue":"12","key":"2025071502114127100_CIT0028","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","article-title":"Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis","volume":"65","author":"Fasanmade","year":"2009","journal-title":"Eur J Clin Pharmacol."},{"issue":"5","key":"2025071502114127100_CIT0029","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.gastrohep.2024.01.007","article-title":"Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn\u2019s Disease and Ulcerative Colitis. Monitorizaci\u00f3n terap\u00e9utica de los f\u00e1rmacos biol\u00f3gicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Espa\u00f1ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)","volume":"47","author":"Rodr\u00edguez-Moranta","year":"2024","journal-title":"Gastroenterol Hepatol."},{"issue":"9","key":"2025071502114127100_CIT0030","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otaf023\/63593537\/otaf023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/3\/otaf023\/63593537\/otaf023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/3\/otaf023\/63593537\/otaf023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T06:11:49Z","timestamp":1752559909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otaf023\/8175227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7,9]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otaf023","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,27]]},"article-number":"otaf023"}}